X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Pink Kush (delta-9 tetrahydrocannabinol) is a CB2/CB1 receptor partial agonist, which is approved in combination with Cannabigerol for the treatment of stress, pain and depression.
Lead Product(s): Tetrahydrocannabinol,Cannabigerol
Therapeutic Area: Psychiatry/Psychology Product Name: Pink Kush
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
EMWA 2024
Not Confirmed
Contact SupplierDetails:
New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.
Lead Product(s): Cannabigerol,Cannabidiol
Therapeutic Area: Neurology Product Name: CBG:CBD
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
EMWA 2024
Not Confirmed
Contact SupplierDetails:
Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.
Lead Product(s): Cannabidiol,Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
EMWA 2024
Not Confirmed
Contact Supplier
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 04, 2023
Details:
The company will use the proceeds for developing its proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 02, 2023
Details:
The collaboration aims to focus on Avicanna’s proprietary formulations and pharmaceutical pipeline including, RHO Phyto having diverse range of proprietary formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids.
Lead Product(s): Cannabidiol,Cannabigerol,Tetrahydrocannabinol
Therapeutic Area: Neurology Product Name: RHO Phyto
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Applied Research Centre at Langara College
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 13, 2023
Details:
Through the license and supply agreement, the South American pharmaceutical company will license Avicanna’s intellectual property and supply finished pharmaceutical products starting initially with its proprietary 10% cannabidiol oral preparation, marketed under the RHO Phyto.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol,Cannabigerol
Therapeutic Area: Neurology Product Name: Rho Phyto
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 13, 2022
Details:
According to the research by Oregon state university Hemp Comound, Cannabigerolic Acid has a good safety profile in humans and are effective against variants of SARS-CoV-2 including variant.
Lead Product(s): Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2022
Details:
HUM-234 was shown to prevent weight gain in mice fed a high fat diet, and importantly abrogated the development of fatty liver (steatosis), a condition clinically associated with multiple metabolic disorders, including diabetes and obesity and a precursor to liver fibrosis.
Lead Product(s): Cannabigerol
Therapeutic Area: Neurology Product Name: HUM-234
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2021
Details:
The programs include in-vitro study of thin film delivery of cannabigerol and quercetin for potential anti-bacterial and anti-viral treatments as well as development of point-of-care sensor-film.
Lead Product(s): Cannabigerol
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Medipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
